Medifast Q3 2026 Revenue Hits $72M as Non-GAAP Loss Beats Estimates by $0.16 Per Share

Medifast reported third-quarter 2026 revenue of $72.05 million, beating analyst expectations by $0.75 million, as the metabolic health company continued its transition around its Trilivy science-backed health system. The company posted a GAAP net loss of $17.5 million, or $1.57 per diluted share, but on a non-GAAP adjusted basis the loss narrowed to $2.1 million, or $0.19 per share, beating consensus estimates by $0.16.

The quarter included 10,200 independent active earning coaches, generating revenue per active earning coach of $7,064. Full-year guidance came in slightly above expectations, contributing to a roughly 5.3% gain in the stock in pre-market trading following the release.